Work

A pharmacokinetic (PK) and pharmacodynamic (PD) biomarker-driven phase I study of intermittent, low dose intensity schedules of the dual MEK/RAF inhibitor, RO5126766 (RO) in patients (pts) with advanced solid tumors.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.104

Authors: Maria Jose de Miguel Luken, Desamparados Roda, Raquel Perez Lopez, Begona Jimenez, Hasina Hassam, Nitharsan Sathiyayogan, Mona Parmar, Alison Joanne Turner, Emma Hall, Nina Tunariu, L Rhoda Molife, Timothy Anthony Yap, Johann Sebastian De Bono, Udai Banerji

Institutions: Institute of Cancer Research, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597480856

Cites:

Cited by: 1

Related to: 10